COMMUNIQUÉS West-GlobeNewswire

-
Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research
14/07/2025 -
Hydreight Technologies Signs Binding Letter of Intent to Acquire 5% Equity Stake in Perfect Scripts, LLC, with Option to Increase to 40%, and Establish Strategic Partnership
14/07/2025 -
Gero Appoints Longevity Expert Dr. Brian Kennedy to Board of Directors
14/07/2025 -
Synergy CHC Corp. (NASDAQ: SNYR) Secures Retail Deals with McKesson Canada and Others as FOCUSfactor Expansion Surges Across North America
14/07/2025 -
Santé Canada étend l’approbation d’Evkeeza® (évinacumab) chez les enfants âgés d’à peine 6 mois atteints d’hypercholestérolémie familiale homozygote (HFHo)
14/07/2025 -
Health Canada Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)
14/07/2025 -
JenaValve Announces First Patient Enrolled in ARTIST Randomized Controlled Trial (RCT) Evaluating the Trilogy™ System in Aortic Regurgitation (AR)
14/07/2025 -
Recludix Pharma Announces Strengthening of Leadership Team, Including Promotion of Dr. Brian Hodous to Chief Scientific Officer
14/07/2025 -
Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive
14/07/2025 -
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat
14/07/2025 -
Real World Data Supports Results of Route 92 Medical’s SUMMIT MAX Clinical Trial
14/07/2025 -
Full Alliance Group Launches Qubitera Holdings, to Develop Quant Blockchain and YAHBEE Wallet for Healthcare and Web3
14/07/2025 -
Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
14/07/2025 -
Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard
14/07/2025 -
Disc Medicine Appoints Nadim Ahmed to its Board of Directors
14/07/2025 -
Vivos Inc. Submitted the Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Clinic
14/07/2025 -
Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™
14/07/2025 -
Borvo EVAC™ System Demonstrates 100% Success Rate in Chronic Subdural Hematoma Clinical Cases Validated Across 5 Medical Centers
14/07/2025 -
NEXGEL and STADA AG Announce Expansion of Partnership for North America
14/07/2025
Pages